Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.

Krzyzanski W, Sutjandra L, Perez-Ruixo JJ, Sloey B, Chow AT, Wang YM.

Pharm Res. 2013 Mar;30(3):655-69. doi: 10.1007/s11095-012-0894-2. Epub 2012 Dec 19.

PMID:
23250851
2.

Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Wang YM, Krzyzanski W, Doshi S, Xiao JJ, PĂ©rez-Ruixo JJ, Chow AT.

AAPS J. 2010 Dec;12(4):729-40. doi: 10.1208/s12248-010-9234-9. Epub 2010 Oct 21.

3.

Romiplostim dose-response in patients with myelodysplastic syndromes.

Perez Ruixo JJ, Doshi S, Wang YM, Mould DR.

Br J Clin Pharmacol. 2013 Jun;75(6):1445-54. doi: 10.1111/bcp.12041.

4.

Romiplostim in chronic immune thrombocytopenic purpura.

Cersosimo RJ.

Clin Ther. 2009 Sep;31(9):1887-907. doi: 10.1016/j.clinthera.2009.09.013. Review.

PMID:
19843480
5.

Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism.

Wang YM, Sloey B, Wong T, Khandelwal P, Melara R, Sun YN.

Pharm Res. 2011 Aug;28(8):1931-8. doi: 10.1007/s11095-011-0420-y. Epub 2011 Apr 8.

PMID:
21476045
6.

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.

Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S.

Blood. 2011 Jul 7;118(1):28-36. doi: 10.1182/blood-2010-10-313908. Epub 2011 Apr 18.

7.

Development of romiplostim: a novel engineered peptibody.

Yang AS.

Semin Hematol. 2015 Jan;52(1):12-5. doi: 10.1053/j.seminhematol.2014.10.007. Epub 2014 Oct 31. Review.

PMID:
25578414
8.

Romiplostim: a novel thrombopoiesis-stimulating agent.

Perreault S, Burzynski J.

Am J Health Syst Pharm. 2009 May 1;66(9):817-24. doi: 10.2146/ajhp080524. Review.

PMID:
19386944
9.

Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.

Sekeres MA, Giagounidis A, Kantarjian H, Mufti GJ, Fenaux P, Jia C, Yang AS, Platzbecker U.

Br J Haematol. 2014 Nov;167(3):337-45. doi: 10.1111/bjh.13037. Epub 2014 Jul 14.

PMID:
25039607
10.

Romiplostim for the treatment of primary immune thrombocytopenia.

Janssens A.

Expert Rev Hematol. 2012 Apr;5(2):133-44. doi: 10.1586/ehm.12.6.

PMID:
22475281
11.

Romiplostim dose response in patients with immune thrombocytopenia.

Perez-Ruixo JJ, Green B, Doshi S, Wang YM, Mould DR.

J Clin Pharmacol. 2012 Oct;52(10):1540-51. Epub 2011 Dec 13.

PMID:
22167563
12.

Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.

Samtani MN, Perez-Ruixo JJ, Brown KH, Cerneus D, Molloy CJ.

J Clin Pharmacol. 2009 Mar;49(3):336-50. doi: 10.1177/0091270008329559.

PMID:
19246731
13.

Romiplostim: a review of its use in immune thrombocytopenia.

Keating GM.

Drugs. 2012 Feb 12;72(3):415-35. doi: 10.2165/11208260-000000000-00000. Review.

PMID:
22316355
14.
15.

Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.

Matsuki E, Miyakawa Y, Yamane A, Okamoto S.

Exp Hematol. 2011 Aug;39(8):829-36. doi: 10.1016/j.exphem.2011.05.001. Epub 2011 May 7.

PMID:
21605620
16.

The biology of thrombopoietin and thrombopoietin receptor agonists.

Kuter DJ.

Int J Hematol. 2013 Jul;98(1):10-23. doi: 10.1007/s12185-013-1382-0. Epub 2013 Jul 3. Review.

PMID:
23821332
17.

Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.

Deutsch VR, Tomer A.

Br J Haematol. 2013 Jun;161(6):778-93. doi: 10.1111/bjh.12328. Epub 2013 Apr 18. Review.

PMID:
23594368
18.

Romiplostim for management of chemotherapy-induced thrombocytopenia.

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Support Care Cancer. 2014 May;22(5):1217-22. doi: 10.1007/s00520-013-2074-2. Epub 2014 Jan 12.

PMID:
24414994
19.

Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.

Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB.

Blood. 1996 Jul 15;88(2):511-21.

20.

[Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura].

Mingot Castellano ME.

Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:39-43. Spanish.

PMID:
21381287
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk